Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00084
|
|||||
| Drug Name |
Amphetamine
|
|||||
| Synonyms |
Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD); Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD), PharmacoFore; PF-08 (Bio-MD/MPAR/prodrug/oral, ADHD), PharmacoFore
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Attention deficit hyperactivity disorder [ICD11: 6A05] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C9H13N
|
|||||
| Canonical SMILES |
CC(CC1=CC=CC=C1)N
|
|||||
| InChI |
InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3
|
|||||
| InChIKey |
KWTSXDURSIMDCE-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 300-62-9
|
|||||
| Pharmaceutical Properties | Molecular Weight | 135.21 | Topological Polar Surface Area | 26 | ||
| Heavy Atom Count | 10 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 1 | |||
| XLogP |
1.8
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103164180
, 103810791
, 103918755
, 104302255
, 10517686
, 10524938
, 10529136
, 11336166
, 11361405
, 11462377
, 11533323
, 115861
, 117525983
, 125680154
, 126677500
, 127272449
, 127272450
, 127272451
, 127272452
, 127272453
, 15297279
, 24882028
, 26746621
, 31073245
, 3249024
, 35804947
, 36519861
, 36651428
, 39909068
, 46506414
, 47216854
, 48110531
, 48415560
, 49855301
, 49855567
, 51091776
, 5340423
, 53789505
, 57321551
, 57651795
, 608004
, 77830611
, 7978700
, 8150111
, 8151914
, 85209571
, 85756449
, 87765
, 9717
, 99302079
|
|||||
| ChEBI ID |
CHEBI:2679
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | DAT1 | Transporter Info | Sodium-dependent dopamine transporter | Substrate | [2] | |
| NET | Transporter Info | Sodium-dependent noradrenaline transporter | Substrate | [2] | ||
| OCT-3 | Transporter Info | Organic cation transporter 3 | Substrate | [3] | ||
| OCTN2 | Transporter Info | Organic cation/carnitine transporter 2 | Substrate | [4] | ||
| References | ||||||
| 1 | Amphetamine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015 Jan;36(1):41-50. | |||||
| 3 | Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem. 2010 Jul;114(1):142-9. | |||||
| 4 | Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells. J Pharmacol Exp Ther. 2005 Jan;312(1):192-8. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.